Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–239 of 239 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pick's Disease Clear all
Completed Not applicable Interventional

Communication Bridge Speech Therapy Research Study

NCT02439853
View directory record Official record
Conditions
Primary Progressive Aphasia, Frontotemporal Dementia
Interventions
Monthly Check-in Session
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

NCT04539041
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
antisense oligonucleotide, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 14, 2026, 3:37 AM EDT
Terminated Phase 1 Interventional

Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

NCT00410566
View directory record Official record
Conditions
Acid Sphingomyelinase Deficiency, Niemann-Pick Disease
Interventions
rhASM
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 14, 2026, 3:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

NCT04747431
View directory record Official record
Conditions
Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal, C9orf72
Interventions
PBFT02
Drug
Lead sponsor
Passage Bio, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
4
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rural Dementia Caregiver Project

NCT04428112
View directory record Official record
Conditions
Depression, Stress, Psychological, Self Efficacy, Loneliness, Social Isolation, Health Care Utilization, Dementia, Dementia Alzheimers, Dementia of Alzheimer Type, Dementia, Vascular, Dementia Frontal, Dementia, Lewy Body, Dementia, Mixed, Dementia in Parkinsons Disease, Dementia, HIV, Dementia Frontotemporal, Dementia, Multi-Infarct
Interventions
Building Better Caregivers Workshop, Attention Control
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 14, 2026, 3:37 AM EDT
Active, not recruiting Phase 1 Interventional

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

NCT05184569
View directory record Official record
Conditions
Semantic Dementia
Interventions
Verdiperstat
Drug
Lead sponsor
Peter Ljubenkov, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Recruiting Phase 1 Interventional

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

NCT07158905
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease
Interventions
AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo
Biological · Other
Lead sponsor
Institute for Molecular Medicine
Other
Eligibility
65 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Boca Raton, Florida • Miami Lakes, Florida • Stuart, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

NCT07054515
View directory record Official record
Conditions
Niemann-Pick Type C Disease, GM1 Gangliosidosis, GM2 Gangliosidosis
Interventions
AZ-3102, Placebo
Drug
Lead sponsor
Azafaros B.V.
Industry
Eligibility
4 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Oakland, California • Minneapolis, Minnesota • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Gamma-Induction in FrontoTemporal Dementia Trial

NCT04425148
View directory record Official record
Conditions
Frontotemporal Dementia
Interventions
Transcranial Alternating Current Stimulation (tACS), Sham Transcranial Alternating Current Stimulation (sham tACS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)

NCT01626378
View directory record Official record
Conditions
Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions
TRx0237, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 79 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 14, 2026, 3:37 AM EDT
Completed No phase listed Observational

P-glycoprotein Function in Brain Diseases

NCT00677885
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Frontotemporal Lobar Degeneration
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 14, 2026, 3:37 AM EDT
Enrolling by invitation Not applicable Interventional

Primary Progressive Aphasia Multicomponent Language Treatment Study

NCT06649084
View directory record Official record
Conditions
Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia, Nonfluent Aphasia, Progressive, Aphasia, Aphasia, Progressive
Interventions
Multicomponent Lexical Retrieval Training (Multi-LRT), Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA), Multicomponent Communication Partner Training (Multi-CPT)
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Not applicable Interventional Results available

CB3 Pilot (Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia)

NCT05697380
View directory record Official record
Conditions
Aphasia, Primary Progressive Aphasia, Dementia, Communication, Alzheimer Disease
Interventions
Communication Bridge™
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Not applicable Interventional

The Care Ecosystem Consortium Effectiveness Study

NCT05669365
View directory record Official record
Conditions
Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Alzheimers, Frontotemporal Dementia
Interventions
Care Ecosystem
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
San Francisco, California • Torrance, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 14, 2026, 3:37 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls

NCT01147679
View directory record Official record
Conditions
Frontotemporal Dementia, Frontotemporal Degeneration, Alzheimer's Disease, Social Behavior
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2011 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation for Primary Progressive Aphasia

NCT02928848
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 14, 2026, 3:37 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

NCT04374136
View directory record Official record
Conditions
Frontotemporal Dementia
Interventions
Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001, Part 2 (OLE Treatment) - Placebo Switched to AL001
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
25 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 14, 2026, 3:37 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ALS Research Collaborative

NCT06885918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS With Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
ALS Therapy Development Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 14, 2026, 3:37 AM EDT
Not listed Phase 1 Interventional

Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol Cyclo (HPβCD) in Niemann-Pick Disease Type C

NCT03893071
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-β-cyclodextrin
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Not applicable Interventional

A Prospective and Retrospective Cohort Study in Patients With Chronic Forms of Acid Sphingomyelinase Deficiency (ASMD)

NCT04106544
View directory record Official record
Conditions
Sphingomyelin Lipidosis
Interventions
Investigational Procedures
Procedure
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 14, 2026, 3:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study

NCT02850146
View directory record Official record
Conditions
Cognition Disorders
Interventions
18F-AV-1451
Drug
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • New Haven, Connecticut • The Villages, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 14, 2026, 3:37 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 14, 2026, 3:37 AM EDT